Cardiovascular Systems (NASDAQ:CSII) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Volatility & Risk
Cardiovascular Systems has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Cardiovascular Systems and Cytosorbents, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Cardiovascular Systems | 0 | 0 | 7 | 0 | 3.00 |
Cytosorbents | 0 | 0 | 5 | 0 | 3.00 |
Cardiovascular Systems presently has a consensus price target of $47.5714, suggesting a potential upside of 31.67%. Cytosorbents has a consensus price target of $15.00, suggesting a potential upside of 68.54%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Cardiovascular Systems.
Earnings and Valuation
This table compares Cardiovascular Systems and Cytosorbents' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Cardiovascular Systems | $236.54 million | 6.14 | $-27,240,000.00 | ($0.79) | -45.73 |
Cytosorbents | $24.95 million | 15.43 | $-19,270,000.00 | ($0.60) | -14.83 |
Cytosorbents has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cardiovascular Systems and Cytosorbents' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Cardiovascular Systems | -10.12% | -11.43% | -8.36% |
Cytosorbents | -30.45% | -34.37% | -19.74% |
Insider and Institutional Ownership
89.7% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 39.8% of Cytosorbents shares are held by institutional investors. 3.0% of Cardiovascular Systems shares are held by company insiders. Comparatively, 5.7% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Cardiovascular Systems beats Cytosorbents on 7 of the 13 factors compared between the two stocks.